What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Aman U. Buzdar mostly deals with Breast cancer, Internal medicine, Tamoxifen, Anastrozole and Oncology.
His Breast cancer study frequently links to related topics such as Surgery.
Adjuvant therapy is the focus of his Internal medicine research.
His Exemestane study, which is part of a larger body of work in Tamoxifen, is frequently linked to Population, bridging the gap between disciplines.
His study brings together the fields of Cancer and Oncology.
His Gynecology research integrates issues from Tolerability and Randomized controlled trial.
His most cited work include:
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. (1316 citations)
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer (821 citations)
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses (772 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Chemotherapy and Tamoxifen.
The various areas that Aman U. Buzdar examines in his Internal medicine study include Gynecology and Surgery.
His Oncology research incorporates themes from Epirubicin, Estrogen receptor, Disease and Docetaxel.
His work carried out in the field of Breast cancer brings together such families of science as Stage, Regimen, Randomized controlled trial and Adjuvant therapy.
His Chemotherapy research is multidisciplinary, incorporating perspectives in Primary tumor, Metastasis, Metastatic breast cancer and Radiation therapy.
He interconnects Exemestane and Advanced breast in the investigation of issues within Anastrozole.
He most often published in these fields:
- Internal medicine (90.14%)
- Oncology (76.06%)
- Breast cancer (71.83%)
What were the highlights of his more recent work (between 2011-2020)?
- Internal medicine (90.14%)
- Breast cancer (71.83%)
- Oncology (76.06%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Breast cancer, Oncology, Anastrozole and Cancer are his primary areas of study.
His study in the fields of Tamoxifen, Epirubicin and Meta-analysis under the domain of Internal medicine overlaps with other disciplines such as Single-nucleotide polymorphism and Hazard ratio.
His Epirubicin research includes themes of Gynecology and Trastuzumab.
His Oncology research incorporates elements of Immunohistochemistry, Randomization and Pertuzumab.
Aman U. Buzdar combines subjects such as Log-rank test, Cyclophosphamide and Median follow-up with his study of Randomization.
The various areas that Aman U. Buzdar examines in his Pertuzumab study include Regimen, Lapatinib and Chemotherapy.
Between 2011 and 2020, his most popular works were:
- Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study (12 citations)
- Abstract P1-14-02: Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer (2 citations)
- Abstract PD1-04: CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients (1 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Anastrozole and Single-nucleotide polymorphism.
His research on Breast cancer focuses in particular on Epirubicin.
His studies deal with areas such as Log-rank test, Gynecology, Trastuzumab and Randomization as well as Epirubicin.
The concepts of his Randomization study are interwoven with issues in Cancer and Median follow-up.
Aman U. Buzdar integrates Single-nucleotide polymorphism and Affect in his research.
His Residual risk research is multidisciplinary, relying on both Tamoxifen, Clinical endpoint, Receptor and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
